Real-World, Chart Review Study To Determine The Effectiveness Of Freestyle Libre Flash Glucose Monitoring System, In Adults With Type 2 Diabetes In France

This retrospective, real-world, chart review study determined the effectiveness of the FreeStyle Libre Flash Glucose Monitoring SystemTM on HbA1c when used by adults with type 2 diabetes (T2DM) as their standard of care in a real-world setting for between 3 months to 6 months. The study population included adults on a basal-bolus insulin regimen for at least 1 year, with HbA1c between 8.0 and 12.0% (64 to 108 mmol/mol), who had been prescribed and using FreeStyle Libre regularly for at least 3 months. Pregnant patients were excluded, as were patients on dialysis. A total of 88 records from insulin using patients with T2DM from 6 hospital sites in France were included in this chart review. On average, HbA1c was 9.0±0.9% (74.7±9.7 mmol/mol), prior to FreeStyle Libre use, age was 64.4±10.6 years, BMI was 32.9±5.5 kg/m2 and average duration of insulin use 9.9±6.4 years (mean±SD), 24.1% were CSII users, 58.0% of patients were on oral antidiabetic medications (metformin, SU or DPP-4) in addition to basal-bolus and 56.8% were male. CVD, renal and retinopathy complications were reported by 40.9%, 37.5% and 37.5% of patients, respectively. HbA1c results were recorded between 91 to 183 days from the start of use of FreeStyle Libre, between May 2017 and July 2018. To minimise selection bias records were selected on a systematic basis. After at least 3 months of using FreeStyle Libre, HbA1c (primary outcome) was significantly reduced by 0.8±1.1% (mean±SD); p Disclosure H. Hanaire: Research Support; Self; Abbott, Eli Lilly and Company, LifeScan, Inc., Novo Nordisk A/S. Other Relationship; Self; Eli Lilly and Company, Novo Nordisk A/S. P.Y. Benhamou: Board Member; Self; Eli Lilly and Company, Novo Nordisk Inc., Sanofi. Consultant; Self; Abbott. C. Bures: Employee; Self; Abbott Laboratories. Employee; Spouse/Partner; Alere Inc. S. Favre: None. S. Fendri: None. M. Joubert: Board Member; Self; Abbott, Air Liquide, AstraZeneca, Lilly Diabetes, Medtronic, Novo Nordisk A/S. Consultant; Self; Voluntis France. Research Support; Self; Boehringer Ingelheim International GmbH. Speaker’s Bureau; Self; Amgen Inc., LifeScan, Inc., Merck Sharp u0026 Dohme Corp., Sanofi.